InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,598.80
(
1.03%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.29
(
-0.23%
)
Bitcoin
63,590.69
(
0.67%
)

Replies to post #65 on Mawson Infrastructure Group Inc (MIGI)

Replies to #65 on Mawson Infrastructure Group Inc (MIGI)

midastouch017

05/27/16 9:24 AM

#66 RE: midastouch017 #65

In June 2016, Can-Fite plans to report data from a Phase II trial of CF101, conducted by its subsidiary OphthaliX, in the treatment of glaucoma and related syndromes of ocular hypertension.